Results 31 to 40 of about 89,572 (287)

Mesenchymal stem cells desensitize castration-resistant prostate cancer to docetaxel chemotherapy via inducing TGF-β1-mediated cell autophagy

Cell & Bioscience, 2021
Background Mesenchymal stem cells (MSCs) have been proved to drive castration resistant prostate cancer (CRPC). In this study, we aim to investigate the contribution of MSCs to the development of docetaxel resistance in CRPC cells and its potential ...
Yang Yu, Fu-han Yang, Wen-tao Zhang, Ya-dong Guo, Lin Ye, Xu-dong Yao   +5 more
doaj   +1 more source

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer [PDF]

, 2006
A systematic review was performed to evaluate the clinical effectiveness of docetaxel in combination with prednisolone (docetaxel is licensed in the UK for use in combination with prednisone or prednisolone for the treatment of patients with metastatic ...
Riemsma, R., Trowman, R., G Norman, E Fenwick, R Riemsma, Norman, G., Fenwick, E., Birtle, A., Collins, R., K Light, Light, K., A Birtle, Palmer, S., R Collins, S Palmer, R Trowman   +15 more
core   +1 more source

Docetaxel Toxicity Optimization in Esophageal Squamous Cell Carcinoma Cell Line YM-1: A Study of Cell Cycle and Doubling Time Effect

Medical Laboratory Journal, 2021
Background and objectives: Docetaxel is a chemotherapeutic agent commonly used for treatment of many cancers, including esophageal squamous cell carcinoma. Docetaxel induces G2/M phase cell cycle arrest and ultimately cell death.
Boshra haghi, Marie Saghaeian jazi, Mahdi zarie, Ayyoob Khosravi, mahboubeh tajaldini, Jahanbakhsh Asadi   +5 more
doaj  

Formation of Docetaxel-related Substances in the Polymer Particles During Storage and Gamma-treatment

Разработка и регистрация лекарственных средств, 2020
Introduction. Docetaxel is widely used for cancer treatment. Actual issue for newly developed polymer-based Docetaxel formulations is applicability of current quality requirements.
Yu. I. Poltavets, S. V. Aleshin, V. V. Zavarzina, A. I. Murav’eva, A. A. Soboleva, I. A. Tubasheva, S. L. Kuznetsov   +6 more
doaj   +1 more source

Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC) [PDF]

, 2009
Background NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems.
Gyi, Mya, Francis G Gabriel, Sharon Glaysher, Polak, ME, Amer, K, Smith, Mark E., Cree, IA, Bruce Addis, Poole, Matthew, Andreotti, Peter Eugene, Joe Rahamim, Goldthorpe, Zoe, Peregrin, K, Rahamim, Joe, Johnson, Penny, Marta E Polak, Mya Gyi, Poole, M, Glaysher, S, Yiannakis, Dennis, Ian A Cree, Gabriel, Francis G., Johnson, P, Zoe Goldthorpe, Dennis Yiannakis, Amer, Khalil, Addis, Bruce, Amer, Khalid, Peter E Andreotti, Addis, B, Gulliford, Tim J., Modi, Paul, Rahamim, J, Andreotti, PE, Andreotti, Peter E., Polak, Marta E., Gulliford, Tim J, Khalid Amer, Knight, LA, Narayanan, A, Smith, ME, Glaysher, Sharon, Penny Johnson, Peregrin, Katharine, Louise A Knight, Paul Modi, Tim J Gulliford, Goldthorpe, Z, Gyi, M, Addis, B. J., Ajit Narayanan, Mark E Smith, Narayanan, Ajit, Katharine Peregrin, Modi, P, Matthew Poole, Gabriel, FG, Yiannakis, D, Gulliford, TJ, Knight, Louise A., Cree, Ian A.   +60 more
core   +1 more source

Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

BMC Cancer, 2007
Background Previous pharmacokinetic studies with docetaxel have mostly used 3-weekly (75 mg/m2 and 100 mg/m2) or weekly regimens (35–40 mg/m2). The pharmacokinetics and radiosensitizing efficacy of weekly 20 mg/m2 docetaxel, has however not been well ...
Kristensen Vessela, Aamdal Steinar, Andersen Anders, Fr Brunsvig Paal, Olsen Harald   +4 more
doaj   +1 more source

Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel’s activity by suppressing the NF-kB signaling pathway

Frontiers in Oncology, 2022
Ubiquitin-specific protease 8 (USP8) has been recently reported to be involved in tumorigenesis. Prostate cancer (PCa) is the most diagnosed malignancy among men, but USP8’s role in PCa is not yet investigated comprehensively.
Md. Tariqul Islam, Fang-Zhi Chen, Han-Chun Chen, Abdul Wahid   +3 more
doaj   +1 more source

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model [PDF]

, 2016
Docetaxel (Taxotere(®) ) is currently used intravenously as an anticancer agent and is primarily metabolized by Cytochrome P450 3A (CYP3A). The HIV protease inhibitor ritonavir, a strong CYP3A4 inhibitor, decreased first-pass metabolism of orally ...
Schellens, Jan H M, Song, Ji Ying, Jan H.M. Schellens, Rottenberg, Sven, Beijnen, Jos H., Lagas, Jurjen S, Sven Rottenberg, Lagas, Jurjen S., Hendrikx, Jeroen J M A, Jurjen S. Lagas, Song, Ji-Ying, Pharmacoepidemiology and Clinical Pharmacology, Ji‐Ying Song, Hilde Rosing, Schinkel, Alfred H, Sub Clinical Pharmacology, Jeroen J.M.A. Hendrikx, Rosing, Hilde, Jos H. Beijnen, Beijnen, Jos H, Schinkel, Alfred H., Alfred H. Schinkel   +21 more
core   +1 more source

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]

, 2012
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Emmanuel Quinaux, Prudence A Francis, Lynnette Fernández-Cuesta, Dell'Orto, P, P. Falagan Lotsch, C. Oakman, A. D. Leo, Pierre Hainaut, Hainaut, P, Azambuja, Evandro De, P. A. Francis, Magali Olivier, D. Larsimont, Larsimont, D, E. Quinaux, G. Viale, Dolci, M Stella, M. S. Dolci, Martine Piccart-Gebhart, Francis, Prudence A, Oakman, C, Dell'orto, Patrizia, Viale, Giuseppe, Evandro De Azambuja, Priscila Falagan-Lotsch, Olivier, Magali, Crown, John, L. Fernández Cuesta, Ke-seay Smoth, Hainaut, Pierre, John Crown, Fernández-Cuesta, L, Viale, G, Leo, Angelo, Larsimont, Denis, M. Piccart Gebhart, Fernández-Cuesta, Lynnette, de Azambuja, Evandro, Giuseppe Viale, Falagan-Lotsch, P, Crown, J, Patrizia Dell'Orto, Piccart-Gebhart, Martine, M Stella Dolci, Piccart-Gebhart, M, Buyse, Marc, Quinaux, E, Denis Larsimont, M. Olivier, M. Buyse, Catherine Oakman, Quinaux, Emmanuel, P. Dell'orto, Olivier, M, Oakman, Catherine, Dolci, MS, Leo, Angelo Di, Buyse, M, Smoth, Ke-Seay, P. Hainaut, Smoth, KS, Azambuja, ED, Angelo Di Leo, J. Crown, Leo, AD, Dolci, Stella, E. D. Azambuja, Francis, P, Francis, PA, Falagan-Lotsch, Priscila, Marc Buyse, K. Smoth   +71 more
core   +1 more source

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Journal of Biomedical Science, 2022
Background Docetaxel has been approved by USFDA as a first-line treatment for castration-resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate ...
Yu-Ke Fu, Bi-Juan Wang, Jen-Chih Tseng, Shih-Han Huang, Ching-Yu Lin, Ying-Yu Kuo, Tzyh-Chyuan Hour, Chih-Pin Chuu   +7 more
doaj   +1 more source